Drug Price Trends for NDC 70677-1294

Average Pharmacy Cost for 70677-1294

Drug Name	NDC	Price/Unit ($)	Unit	Date
FT MICONAZOLE 1 COMBO PACK	70677-1294-01	11.84038	EACH	2026-04-01

Best Wholesale Price for NDC 70677-1294

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 70677-1294

Last updated: April 3, 2026

What is NDC 70677-1294?

NDC 70677-1294 is an immuno-oncology drug marketed under the trade name of Trodelvy (sacituzumab govitecan-hziy). It is an antibody-drug conjugate (ADC) approved by the U.S. Food and Drug Administration (FDA) for treatment of metastatic triple-negative breast cancer (TNBC) and urothelial carcinoma.

Market Size and Growth Drivers

Current Market Landscape

• The global oncology drug market surpassed USD 150 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6% through 2030 [1].

• Trodelvy's primary indication, metastatic TNBC, affects approximately 15,000 patients annually in the U.S. [2]. The drug's approval expanded its potential to other solid tumors, increasing its patient base.

Key Growth Drivers

• Increasing prevalence of TNBC; estimates suggest 10-15% of breast cancers are triple-negative, with rising incidence due to demographic shifts [3].

• Approval for metastatic urothelial carcinoma allows access to a broader patient population, adding up to 10,000 cases annually in the U.S. [2].

• Growing adoption of antibody-drug conjugates as standard of care in oncology.

Competitive Landscape

• Currently, Trodelvy competes with other immune and targeted therapies such as pembrolizumab, eribulin, and sacituzumab govitecan's closest alternatives.

• Fragmented market with room for growth but high competition from both established treatments and emerging ADCs.

Price Analysis and Projections

Current Pricing

• The average wholesale price (AWP) of Trodelvy is approximately USD 13,800 per vial [4].

• Treatment regimen typically involves multiple doses over several months, resulting in estimated costs between USD 60,000 and USD 180,000 per patient.

Factors Influencing Price Trends

• Patent exclusivity until 2030 limits generic competition; biosimilar competition may emerge post-patent.

• Manufacturing costs are high due to ADC complexity, supporting current premium pricing.

• Payer negotiations, insurance coverage, and patient assistance programs influence actual patient out-of-pocket costs.

Future Price Projections

• Expect stabilization of current prices through 2025 driven by patent protections and manufacturing costs.

• Post-2030, potential price reductions could occur if biosimilars enter the market, with estimates ranging from 20% to 40%.

• Market competition and reimbursement policies may pressure prices downward despite high clinical value.

Revenue Projections

Year	Estimated U.S. Market Revenue	Assumptions
2023	USD 1.2 billion	8,700 treated patients, average USD 80,000 per patient
2025	USD 1.3 billion	Slight increase in adoption, stable prices
2030	USD 1.8 billion	Broadened indications, expanded patient access

Key Market Dynamics

• Uptake is currently moderate due to clinical familiarity and reimbursement landscape.

• Formulary placements will significantly influence revenue growth.

• International markets offer potential but face regulatory and pricing hurdles.

Risks and Opportunities

Risks

• Competition from emerging ADCs and immunotherapies.

• Pricing pressures from payers and health authorities.

• Potential safety concerns impacting adoption.

Opportunities

• Expansion into additional indications, such as other breast and lung cancers.

• Combination therapies enhancing efficacy, justifying higher pricing.

• Strategic partnerships to expand global reach.

Conclusion

NDC 70677-1294 (Trodelvy) maintains a strong growth trajectory driven by increasing indications and market penetration. Pricing is expected to remain stable through 2025, with potential downward adjustments after patent expiration. Revenue growth will depend on market adoption, reimbursement strategies, and competitive developments.

---

Key Takeaways

• The U.S. market for Trodelvy is projected to reach USD 1.3 billion by 2025.

• Pricing remains around USD 13,800 per vial, with treatment costs averaging USD 80,000.

• Patent protections extend until 2030, limiting biosimilar competition until then.

• Market growth hinges on expanded indications and reimbursement policies.

• Post-2030, biosimilar entry may reduce prices by 20–40%.

---

FAQs

1. What are the primary indications for NDC 70677-1294 (Trodelvy)?
   Metastatic triple-negative breast cancer and urothelial carcinoma.

2. How does Trodelvy's price compare with similar therapies?
   It costs approximately USD 13,800 per vial, higher than traditional chemotherapies but comparable with other ADCs.

3. When will biosimilar competition likely impact prices?
   After patent expiration around 2030, with biosimilars potentially reducing prices by 20-40%.

4. What factors influence reimbursement strategies for Trodelvy?
   Clinical efficacy, formulary placement, negotiated discounts, and patient assistance programs.

5. Are international markets a significant growth driver?
   Yes; regulatory approvals and pricing policies in Europe, Asia, and emerging economies can expand revenue streams.

---

References

[1] IBISWorld. (2022). Oncology drug market report.

[2] U.S. Food and Drug Administration. (2022). FDA approval documentation for Trodelvy.

[3] American Cancer Society. (2021). Breast cancer statistics.

[4] Redbook. (2022). Wholesale drug pricing database.